By Cocer Peptides 
Watanni 1 da suka gabata
DUKKANIN LABARI DA BAYANIN KYAUTATAWA DA AKE BAYAR A WANNAN SHAFIN KAWAI DOMIN WATSA BAYANI NE DA MANUFOFIN ILIMI.
Kayayyakin da aka bayar akan wannan gidan yanar gizon an yi niyya ne kawai don binciken in vitro. Binciken in vitro (Latin: *a cikin gilashi*, ma'ana a cikin gilashin gilashi) ana gudanar da shi a wajen jikin mutum. Waɗannan samfuran ba magunguna ba ne, Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da su ba, kuma dole ne a yi amfani da su don hanawa, magani, ko warkar da duk wani yanayi na likita, cuta, ko cuta. Doka ta haramta shigar da waɗannan samfuran cikin jikin mutum ko dabba ta kowace hanya.
Kiba ya zama batun kiwon lafiyar jama'a da ke ƙara tsananta a duk duniya, tare da illa mai yawa akan lafiyar jikin mutane, kamar haifar da cututtukan zuciya, ciwon sukari, da sauran yanayi na yau da kullun. A cikin 'yan shekarun nan, magungunan GLP-1 sun fito a matsayin zaɓin magani mai ban sha'awa a fagen sarrafa kiba.
Hoto 1 Hanyoyin da za a iya yin asarar nauyi ta hanyar GLP-1. GI, Gastrointestinal; GLP-1, Glucagon-kamar peptide-1; GLP-1R, Glucagon-kamar peptide-1 mai karɓa.
Hanyar Ayyukan Magungunan GLP-1 a cikin Maganin Kiba
GLP-1 shine peptide na endogenous wanda ƙwayoyin L ke ɓoye a cikin tsarin endocrine na hanji. Magungunan GLP-1, wanda kuma aka sani da GLP-1 agonists masu karɓa (GLP-1 RAs), suna yin kwaikwayon tasirin physiological na GLP-1 ta hanyar kunna mai karɓar GLP-1 da hanyoyin siginar sa na ƙasa, don haka suna yin tasirin ilimin lissafi daban-daban waɗanda ke taimakawa sarrafa nauyi.
Haɓaka siginar insulin: GLP-1 RAs suna haɓaka fitowar insulin daga ƙwayoyin β na pancreatic ta hanyar dogaro da glucose. Lokacin da matakan glucose na jini ya tashi, GLP-1 RAs suna ɗaure ga masu karɓa na GLP-1 akan saman sel beta na pancreatic, suna kunna hanyoyin siginar intracellular don haɓaka haɓakar insulin da sakin, don haka rage matakan glucose na jini. Tsayar da matakan glucose na jini yana taimakawa rage haɗuwa da kitse da adanawa, yana hana haɓakar ci da samun kiba sakamakon hauhawar glucose na jini.
Rashin cin abinci: GLP-1 RAs suna aiki akan tsarin kulawa na tsakiya, musamman yankunan kwakwalwa da ke hade da tsarin abinci, irin su hypothalamus. Ta hanyar ɗaure masu karɓa na GLP-1 akan saman jijiyoyi na hypothalamic, suna daidaita sakin neuropeptide, kamar rage ɓoyewar peptides masu motsa sha'awa da haɓaka maganganun peptides masu hana ci, ta haka haifar da ma'anar cikawa, rage cin abinci, da samun sarrafa nauyi.
Jinkirta zubar da ciki: GLP-1 RAs yana rage yawan adadin abin da ke cikin ciki ya shiga cikin ƙananan hanji, yana tsawaita lokacin da abinci ya kasance a cikin ciki da kuma samar da ci gaba mai dorewa. Wannan jinkirin zubar da ciki ba kawai yana rage girman abinci ba har ma yana daidaita matakan glucose na jini, yana hana hawan glucose na jini bayan cin abinci kuma ta haka yana rage tarin mai.
Tsarin 1 Tsarin tsari na GLP-1 agonists mai karɓa: rarrabuwa, amincin ƙwayoyi, da inganci. GI, Gastrointestinal; GLP-1R, Glucagon-kamar peptide-1 mai karɓa; PEG, polyethylene glycol.
Aikace-aikacen magungunan GLP-1 a cikin maganin kiba
Maganin kiba na manya: A cikin maganin kiba mai girma, GLP-1 RAs sun sami sakamako mai mahimmanci. An kammala gwajin gwaji na asibiti na Phase III na semaglutide, tare da sakamakon da ke nuna tasirin asarar nauyi. A cikin STEP 2.4 mg / mako semaglutide aikin, marasa lafiya sun sami babban asarar nauyi, yana ƙara tabbatar da ingancin GLP-1 RAs a cikin kula da kiba mai girma. Ana amfani da waɗannan magungunan a matsayin wani ɓangare na cikakken shirin asarar nauyi, haɗe tare da sarrafa abinci da matsakaicin motsa jiki, don cimma sakamako mafi kyau na asarar nauyi.
Maganin kiba na yara: Nazarin baya-bayan nan sun nuna cewa an yi amfani da magungunan GLP-1 irin su exenatide, semaglutide, da liraglutide don magance yanayin kiba na yara, kamar kiba mai tsanani, kiba mai alaƙa da ciwon ovary na polycystic (PCOS), da kuma kiba na hypothalamic. Misali, binciken ya gano cewa wadannan kwayoyi suna da wani tasiri wajen sarrafa kiba a cikin yara, suna taimakawa wajen inganta sigogi na rayuwa, da samar da sabbin hanyoyin magance kiba na yara.
Maganin kiba ga mutane na musamman - Marasa lafiya na PCOS: Polycystic ovary syndrome (PCOS) cuta ce ta endocrin gama gari tsakanin mata masu haihuwa, kuma kiba ya zama ruwan dare tsakanin majinyatan PCOS. GLP-1 RAs suna da fa'idodi na musamman a cikin magance kiba a cikin marasa lafiya na PCOS. Nazarin ya nuna cewa GLP-1 far ba kawai rage nauyi a cikin PCOS marasa lafiya amma kuma inganta insulin juriya, saukar da hyperandrogenism, har ma da kara da damar na halitta tunani da kuma in vitro hadi. Wannan ya sa GLP-1 RA azaman zaɓin magani mai ban sha'awa ga majinyata PCOS masu kiba, suna ba da sabbin hanyoyin inganta lafiyarsu da haihuwa.
Kammalawa
A taƙaice, magungunan GLP-1, a matsayin ƙarfin da ke tasowa a fagen jiyya na kiba, suna nuna alamun aikace-aikacen da ke da alaƙa a cikin kula da kiba a cikin manya, yara, da al'ummomi na musamman (kamar marasa lafiya na PCOS) saboda tsarin aikin su na musamman. Ta hanyoyi da yawa, ciki har da inganta ƙwayar insulin, hana ci abinci, da jinkirta zubar da ciki, GLP-1 RAs yana taimakawa marasa lafiya su rage nauyi da inganta yanayin rayuwa.
A cikin maganin kiba na manya, magunguna irin su liraglutide da semaglutide an inganta su ta hanyar gwaji na asibiti, suna ba da amintattun zaɓuɓɓukan jiyya ga marasa lafiya masu kiba. A cikin kula da kiba a cikin marasa lafiya na PCOS, GLP-1 RA ba kawai taimakawa rage nauyi ba amma kuma inganta ingantaccen cututtukan endocrine da ke hade da yanayin, yana ba da fa'idodi da yawa ga marasa lafiya na PCOS.
Sources
[1] Zhang D, Lu H. GLP-1RA: Sabon Bege a Farkon Kiba[J]. Jaridar Biosciences da Magunguna, 2025,13 (2): 465-479. https://cstj.cqvip.com/Qikan/Article/Detail?id=HS727602025002035
[2] Kavarian PN, Mosher TL, Haija MA E. Amfani da glucagon-like-peptide 1 agonist mai karɓa a cikin maganin kiba na yara.[J]. Ra'ayi na Yanzu a Likitan Yara, 2024,36 5:542-546. https://api.semanticcholar.org/CorpusID:272115519
[3] Wang JY, Wang QW, Yang XY, et al. GLP-1 agonists mai karɓa don maganin kiba: Matsayi a matsayin hanya mai ban sha'awa [J]. Iyaka a cikin Ilimin Ilimin Halittu, 2023,14:1085799.DOI:10.3389/fendo.2023.1085799.
[4] Pedrosa MR, Franco DR, Gieremek HW, et al. GLP-1 Agonist don Magance Kiba da Hana Ciwon Zuciya: Menene Muka Cimma Ya zuwa yanzu?[J]. Rahoton Atherosclerosis na Yanzu, 2022,24(11):867-884.DOI:10.1007/s11883-022-01062-2.
[5] Baranowska-Bik A. Maganin kiba a cikin mata masu PCOS ta amfani da analogues GLP-1 - fa'idodi da iyakancewa [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia][J]. Endokrynologia Polska, 2022,73 (3): 627-643.DOI: 10.5603/EP.a2022.0047.
